Evidence map›Paper›PMID 34878564›Full record

ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2022

[Disinfectants during the COVID-19 pandemic: a challenge].

Maren Eggers, Anna Baumann, Nils Lilienthal, Eike Steinmann, Jochen Steinmann, Nils-Olaf Hübner, Holger F Rabenau, Viola Weinheimer, Ingeborg Schwebke

Open access · hybridAbstract readReview
In one paragraph

Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Maren EggersKommission für Virusdesinfektion, Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V., Geschäftsstelle Kiel, Kiel, Deutschland. eggers@labor-enders.de.
Anna BaumannBundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bonn, Deutschland.
Nils LilienthalBundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bonn, Deutschland.
Eike SteinmannAbteilung für Molekulare & Medizinische Virologie, Ruhr-Universität Bochum, Bochum, Deutschland.
Jochen SteinmannDr. Brill + Partner GmbH Institut für Hygiene und Mikrobiologie, Bremen, Deutschland.
Nils-Olaf HübnerInstitut für Hygiene und Umweltmedizin, Universitätsmedizin Greifswald, Greifswald, Deutschland.
Holger F RabenauInstitut für Medizinische Virologie, Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Deutschland.
Viola WeinheimerBundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA), Dortmund, Deutschland.
Ingeborg SchwebkeKommission für Virusdesinfektion, Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V., Geschäftsstelle Kiel, Kiel, Deutschland.
Federal Institute for Drugs and Medical Devices · DEDr. Brill + Dr. Steinmann (Germany) · DEFederal Institute for Occupational Safety and Health · DEInstitut für Hygiene und Umwelt · DERuhr University Bochum · DEUniversity Hospital Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disinfection measures have become more important as a result of the COVID-19 pandemic in Germany. The increased need for disinfectants at the beginning of the pandemic required temporary legal regulations in order to provide a sufficient quantity of products for the necessary disinfection in the medical sector on the one hand and for the additional demand in the population on the other. For this purpose, the Federal Institute for Drugs and Medical Devices (BfArM) and the Federal Institute for Occupational Safety and Health (BAuA) issued a general ruling, which is explained in more detail in this article. The focus was on measures for hygienic hand disinfection. However, other applications such as surface disinfection in relation to pandemic respiratory diseases are also addressed. The experience gained in ensuring the supply of disinfectants that are effective and safe to use should be used to prepare for further pandemics.

Indexed as

COVID-19DisinfectantsDisinfectionGermanyHumansPandemicsSARS-CoV-2DisinfectantsBiocidal productsCoronavirus SARS-CoV-2DisinfectionGeneral rulingMedicinal products

Identifiers

PMID34878564
PMCPMC8652094
OpenAlexW4200369520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.